GENinCode (LON:GENI) Reaches New 52-Week Low – Time to Sell?

GENinCode Plc (LON:GENI) shares reached a new 52-week low during mid-day trading on Monday . The stock traded as low as GBX 0.75 and last traded at GBX 0.78, with a volume of 300338 shares trading hands. The stock had previously closed at GBX 0.78.

GENinCode Stock Performance

The company has a market capitalization of £6.41 million, a price-to-earnings ratio of -0.41 and a beta of 0.59. The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.88 and a current ratio of 0.93. The company’s fifty day simple moving average is GBX 0.91 and its two-hundred day simple moving average is GBX 1.08.

GENinCode (LON:GENI) last released its earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share for the quarter. The company had revenue of GBX 308 million during the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%. Equities research analysts predict that GENinCode Plc will post -7.1299999 earnings per share for the current fiscal year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.